Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10163560 | 0.93 | L3MBTL1 (0.39) | POLBCCNE1CDK2MMP13ADAMTS4 | |
| SCHEMBL10162853 | 0.91 | POLB (0.39) | POLBMMP13ADAMTS4MMP3MMP8 | |
| SCHEMBL8219963 | 0.91 | MAPK1 (0.41) | ROCK2POLBMMP13ADAMTS4MMP3 | |
| SCHEMBL10208202 | 0.91 | ENPP2 (0.43) | ROCK2POLBMMP13ADAMTS4MMP3 | |
| SCHEMBL10163597 | 0.90 | POLB (0.38) | POLBMMP13ADAMTS4MMP3MMP8 | |
| SCHEMBL10162873 | 0.89 | TP53 (0.44) | NAMPTPOLBMMP13ADAMTS4MMP3 | |
| SCHEMBL10162848 | 0.88 | POLB (0.48) | POLBMMP13ADAMTS4MMP3MMP8 | |
| SCHEMBL8229567 | 0.88 | ROCK2 (0.42) | ROCK2POLBMMP13ADAMTS4MMP3 | |
| SCHEMBL8229558 | 0.87 | MMP13 (0.40) | CYP2C9NAMPTROCK2POLBMMP13 | |
| SCHEMBL8225302 | 0.86 | HPGD (0.40) | POLBMMP13ADAMTS4MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | CYP2C9 468/4885NAMPT 536/4885ROCK2 1967/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | CYP2C9 468/4885NAMPT 536/4885ROCK2 1967/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CYP2C9 468/4885NAMPT 536/4885ROCK2 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.